NCT01258751View on ClinicalTrials.gov

This Study Will Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding In Brain Using PET (Positron Emission Tomography) In Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions
Healthy
Interventions
DRUG

PF-05212377

Single dose of up to 70 mg PF-05212377, delivered as .25 mg, 5 mg and/or 15 mg on study day 1

Trial Locations (3)

06511

Pfizer Investigational Site, New Haven

06519

Pfizer Investigational Site, New Haven

06520

Pfizer Investigational Site, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
collaborator

Yale University

OTHER

lead

Pfizer

INDUSTRY

NCT01258751 - This Study Will Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding In Brain Using PET (Positron Emission Tomography) In Healthy Volunteers | Biotech Hunter | Biotech Hunter